ストックスクリーナーアプリを入手
133.72
1.62%
2.585
前日終値:
$131.14
開ける：
$130.77
24時間の取引高:
361.53K
Relative Volume:
0.22
時価総額：
$19.59B
収益：
$9.82B
当期純損益:
$1.48B
株価収益率:
13.20
EPS:
10.13
ネットキャッシュフロー:
$2.30B
1週間 パフォーマンス:
+3.80%
1か月 パフォーマンス:
+7.88%
6か月 パフォーマンス:
-17.15%
1年 パフォーマンス:
-42.01%
1日の値動き範囲:
$129.51
$133.80
1週間の範囲:
$126.87
$133.80
52週間の値動き範囲:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
BIIB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
133.71 | 18.81B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
752.17 | 651.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.92 | 368.73B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
187.29 | 328.06B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.90 | 223.60B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.26 | 312.99B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Ex-Biogen Chief Medical Officer Strengthens Entrada's Duchenne Program as Phase 1 Data Shows Promise - Stock Titan
Neuromuscular Disease Therapeutics Market Growth Driven - openPR.com
152,867 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
First County Bank CT Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Lansforsakringar Fondforvaltning AB publ Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
City Therapeutics Partners with Biogen - Global Legal Chronicle
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc. (NASDAQ:BIIB) Holdings Raised by Centre Asset Management LLC - MarketBeat
California State Teachers Retirement System Buys 2,811 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Toronto Dominion Bank Has $11.11 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Siemens Fonds Invest GmbH - MarketBeat
Farmers Trust Co. Buys 2,012 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
William Blair Brokers Lower Earnings Estimates for Biogen - MarketBeat
Lighthouse Financial LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Auxier Asset Management Sells 2,136 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Mackenzie Financial Corp - MarketBeat
GF Fund Management CO. LTD. Makes New $5.24 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Progressive Supranuclear Palsy Treatment Market Set to Witness GrowthBiogen, AbbVie - openPR.com
PKO Investment Management Joint Stock Co Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen and City Therapeutics partner to develop RNAi therapies - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by USS Investment Management Ltd - MarketBeat
Public Employees Retirement System of Ohio Sells 2,866 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Voloridge Investment Management LLC Invests $23.20 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $234.55 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Tauopathies Treatment Market Detailed in New Research ReportBiogen, AbbVie - openPR.com
Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com
Recombinant Dna Technology Market Generated Opportunities, - openPR.com
In Vitro Monoclonal Antibodies Market is expected to reach US$ - openPR.com
Biogen and City Therapeutics to develop RNAi therapy - Yahoo Finance
Biogen and City Therapeutics partner to advance RNAi therapies - World Pharmaceutical Frontiers
Woodline Partners LP Boosts Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential - Investing.com
Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential By Investing.com - Investing.com UK
Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal - Yahoo Finance
Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal - simplywall.st
Biogen partners with John Maraganore’s new RNAi startup - The Business Journals
Biogen (BIIB) Partners with City Therapeutics for RNAi Therapies - GuruFocus
Biogen strikes RNAi deal with City; Aurion withdraws IPO - BioPharma Dive
City hits the town with $1B-plus deal with Biogen - BioWorld MedTech
Biogen and City Therapeutics collaborate on RNAi meds - The Pharma Letter
Biogen taps City Therapeutics in RNAi deal worth up to $1B - Endpoints News
Biogen (BIIB) Collaborates with City Therapeutics on RNAi Therap - GuruFocus
Biogen and City Therapeutics Announce Strategic Research Collabo - GuruFocus
Biogen (BIIB) Collaborates with City Therapeutics on RNAi Therapies | BIIB Stock News - GuruFocus
Biogen Partners City Therapeutics To Develop Select Novel RNAi Therapies - Nasdaq
Biogen And City Therapeutics Announce Strategic Research Collaboration To Develop Select Novel Rnai-Based Therapies - marketscreener.com
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
0.47%
大文字化:
|
ボリューム (24 時間):